Core Viewpoint - ADMA Biologics (ADMA) shows significant upside potential with a mean price target of $27.33, indicating a 51.8% increase from the current trading price of $18.01 [1] Price Targets and Analyst Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $4.04, where the lowest estimate of $25 suggests a 38.8% increase, and the highest estimate of $32 indicates a potential surge of 77.7% [2] - A low standard deviation among price targets suggests strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [8] Earnings Estimates and Analyst Sentiment - Analysts exhibit growing optimism about ADMA's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which correlates strongly with near-term stock price movements [10] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 2.2%, with one estimate moving higher and no negative revisions [11] - ADMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, further supporting the stock's potential upside [12]

Core Viewpoint - ADMA Biologics, Inc. emphasizes its strategic advantage due to fully U.S.-based manufacturing and supply chain operations, which are insulated from recent tariffs on foreign goods [1][2]. Group 1: Company Overview - ADMA Biologics is a biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [3]. - The company currently offers three FDA-approved plasma-derived biologics: ASCENIV™, BIVIGAM®, and NABI-HB®, targeting immune deficiencies and hepatitis B [3]. - ADMA operates an FDA-licensed facility in Boca Raton, Florida, for the production of its immune globulin products and also runs FDA-approved source plasma collection through its subsidiary, ADMA BioCenters [3]. Group 2: Strategic Positioning - The company asserts that the tariffs on foreign goods will not affect its supply chain or production operations due to its fully integrated U.S.-based supply chain [2]. - ADMA's operational model ensures enhanced supply chain robustness, resilience, and regulatory compliance, aligning with federal and private sector preferences for U.S.-made products [2]. - By maintaining complete operational control within the U.S., ADMA is positioned to leverage national economic incentives and provide reliable, high-quality offerings to its domestic customers [2].

Technical Analysis - ADMA Biologics Inc has reached a key level of support, with its 50-day simple moving average crossing above the 200-day simple moving average, indicating a "golden cross" [1] - A golden cross is a bullish technical chart pattern that suggests a potential breakout, formed when a stock's short-term moving average surpasses its long-term moving average [1][2] Market Performance - ADMA has experienced a rally of 31% over the past four weeks, indicating strong upward momentum [3] - The company currently holds a 2 (Buy) rating on the Zacks Rank, suggesting positive market sentiment [3] Earnings Outlook - The earnings outlook for ADMA is positive, with no earnings estimates decreasing in the past two months and two revisions higher, leading to an increase in the Zacks Consensus Estimate [3] - This positive earnings outlook further solidifies the bullish case for ADMA [3] Investment Consideration - Investors are encouraged to consider adding ADMA to their watchlist due to the significant technical indicator and the positive movement in earnings estimates [4]

Core Viewpoint - Adma Biologics has shown strong stock performance recently, significantly outperforming the broader market and its industry, raising questions about its future trajectory [2][16]. Earnings Estimate Revisions - For the current quarter, Adma Biologics is expected to report earnings of $0.16 per share, reflecting a 100% increase year-over-year, with a 6.7% upward revision in estimates over the last 30 days [5]. - The consensus earnings estimate for the current fiscal year is $0.71, indicating a 44.9% year-over-year increase, with a 3.7% upward revision in the last month [5]. - For the next fiscal year, the consensus estimate is $0.93, representing a 31% increase from the previous year, with a 6.9% upward revision [6]. - The Zacks Rank for Adma Biologics is 2 (Buy), indicating a positive outlook based on recent earnings estimate revisions [7]. Revenue Growth Forecast - The consensus sales estimate for the current quarter is $119.1 million, showing a year-over-year increase of 45.5% [9]. - For the current fiscal year, the sales estimate is $495.8 million, indicating a 16.3% increase, while the next fiscal year's estimate is $611.5 million, reflecting a 23.3% increase [9]. Last Reported Results and Surprise History - In the last reported quarter, Adma Biologics achieved revenues of $117.55 million, a 59.1% year-over-year increase, and an EPS of $0.14 compared to $0.04 a year ago [11]. - The company exceeded consensus revenue estimates in all four of the last quarters and surpassed EPS estimates three times [11]. Valuation - Adma Biologics has a Zacks Value Style Score of D, indicating it is trading at a premium compared to its peers [15].

Group 1 - The article emphasizes that it is not an exhaustive analysis of the featured company and should not be interpreted as personalized investment advice [2] - It highlights that the predictions and opinions presented are based on the author's analysis and reflect a probabilistic approach, not absolute certainty [2] - The article advises readers to independently verify the information and conduct their own research before making investment decisions [2] Group 2 - The content clarifies that past performance is not a guarantee of future results and no specific investment recommendations are provided [3] - It notes that the views expressed may not reflect those of Seeking Alpha as a whole, indicating a diversity of opinions among analysts [3] - The article mentions that analysts may not be licensed or certified by any institute or regulatory body, which could impact the credibility of the analysis [3]

Core Viewpoint - Adma Biologics (ADMA) shares have increased by 22.2% in the past four weeks, closing at $19.65, with a potential upside of 39.1% based on Wall Street analysts' mean price target of $27.33 [1] Price Targets - The average price target consists of three estimates ranging from a low of $25 to a high of $32, with a standard deviation of $4.04, indicating a potential increase of 27.2% to 62.9% from the current price [2] - A low standard deviation suggests a strong agreement among analysts regarding the price movement of ADMA shares, which can serve as a starting point for further research [7] Analyst Sentiment - Analysts have shown increasing optimism about ADMA's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [9] - Over the last 30 days, two earnings estimates for ADMA have been revised upward, leading to a 3.7% increase in the Zacks Consensus Estimate [10] Zacks Rank - ADMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside [11] Conclusion on Price Targets - While consensus price targets may not be entirely reliable for predicting stock gains, they can provide a useful guide for understanding potential price movements [12]

Company Overview - Adma Biologics (ADMA) shares increased by 10.2% to close at $20.61, with a notable trading volume compared to normal sessions, and a total gain of 15.7% over the past four weeks [1][2] Revenue Growth - In 2024, Adma Biologics reported total revenues of $426.5 million from product sales, marking a 65% year-over-year increase [2] Earnings Expectations - The company is projected to report quarterly earnings of $0.16 per share, reflecting a 100% year-over-year change, with expected revenues of $119.1 million, up 45.5% from the same quarter last year [3] Earnings Estimate Revisions - The consensus EPS estimate for the upcoming quarter has been revised 6.7% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] Industry Context - Adma Biologics operates within the Zacks Medical - Biomedical and Genetics industry, where Wave Life Sciences (WVE) has seen a 2.6% increase in its stock price, but has returned -11.2% over the past month [4]

Financial Performance - For the year ended December 31, 2024, ADMA Biologics achieved a net income of $197.7 million, marking the first time in its history that it reported net income on a GAAP basis [337]. - Total revenues for the year ended December 31, 2024, were $426.5 million, an increase of $168.2 million or 65% compared to $258.2 million in 2023 [355]. - Gross profit for 2024 was $219.6 million, representing a gross margin of 51.5%, up from 34.4% in 2023 [357]. - Net income for the year ended December 31, 2024, was $197.7 million, an improvement of $225.9 million compared to a net loss of $28.2 million in 2023 [367]. - Adjusted EBITDA for 2024 was $164.6 million, compared to $40.3 million in 2023, reflecting significant operational improvements [354]. - The company expects Adjusted Net Income to exceed $175 million and $235 million in fiscal years 2025 and 2026, respectively [333]. - The company reported pre-tax income and GAAP net income of $125.7 million and $197.7 million for the year ended December 31, 2024, respectively [389]. Revenue Growth - The increase in revenues was primarily driven by higher sales of ASCENIV and other immunoglobulin products, along with a $2.2 million increase in plasma sales [355]. - ASCENIV's prescriber and patient base expanded during 2024, leading to record utilization and sustained demand trends into 2025 [339]. - The company expects further shifts in revenue mix toward higher margin IVIG products in fiscal 2025 [357]. - Total revenues for the year ended December 31, 2023, were $258.2 million, an increase of $104.1 million or approximately 68% compared to $154.1 million in 2022 [369]. Operational Efficiency - The company generated positive cash flow from operations of $118.7 million, primarily driven by substantial revenue growth and acceptance of ASCENIV [337]. - Positive cash flow from operations was $118.7 million for the year ended December 31, 2024, compared to $8.8 million for the year ended December 31, 2023 [387]. - Research and development expenses decreased to $1.8 million in 2024 from $3.3 million in 2023, primarily due to the absence of expenditures related to BIVIGAM [358]. - Plasma center operating expenses significantly decreased from $17.8 million in 2022 to $4.3 million in 2023, attributed to increased plasma collection efficiency [373]. Debt and Financing - The company entered into a senior secured credit facility with Ares Capital Corporation, providing $135.0 million in total, including a term loan of $62.5 million and a revolving credit facility of $72.5 million [391]. - As of December 31, 2024, the outstanding balance on the revolving credit facility was $42.5 million, and the term loan balance was $32.5 million [392]. - The interest rate on the term loan was approximately 10.9% and on the revolving facility was approximately 8.3% as of December 31, 2024 [393]. - The company incurred a loss on the extinguishment of the Hayfin Credit Facility amounting to $26.2 million in the year ended December 31, 2023 [391]. - Net cash used in financing activities for 2024 was $58.3 million, primarily due to $60.0 million in debt principal payments [409]. Future Outlook - The company anticipates filing a supplemental Biologics License Application for ASCENIV in mid-2025, with potential FDA approval in the first half of 2026 for pediatric use [340]. - The company expects total capital expenditures for fiscal 2025 to be between $12.0 million and $18.0 million [408]. - The company anticipates that its current cash, cash equivalents, and accounts receivable will be sufficient to fund operations through the end of the first quarter of fiscal 2026 [389]. Strategic Initiatives - The company is exploring various strategic alternatives and value-creating opportunities as a top corporate priority [390]. - ADMA's Boca Facility has a peak annual processing capability of up to 600,000 liters, with projected annual revenues exceeding $490 million in 2025 and $605 million in 2026 [333]. - The innovative yield enhancement production process, submitted for FDA approval in December 2024, is expected to increase production yields by approximately 20% if approved [334]. Cost Management - Selling, general and administrative expenses increased to $74.1 million in 2024, reflecting a $6.4 million rise in stock-based compensation [361]. - Interest expense decreased to $13.9 million in 2024 from $25.0 million in 2023, due to a reduction in debt principal and lower interest rates [363]. - Inflation has impacted various aspects of the business, leading to increased costs for raw materials, labor, and transportation, with expectations for some relief in 2025 [411]. - The company does not currently utilize derivative financial instruments to mitigate interest rate risk associated with its senior credit facility [412]. - A hypothetical 100 basis points increase in interest rates would have an approximate $0.8 million annualized negative impact on the company's earnings and cash flows [412].

Group 1 - Adma Biologics closed at $18.67, with a +1.3% increase, outperforming the S&P 500's gain of 0.64% [1] - The stock has gained 15.91% over the past month, contrasting with the Medical sector's loss of 0.88% and the S&P 500's loss of 7.69% [1] Group 2 - The upcoming earnings release is expected to show an EPS of $0.16, representing a 100% increase from the prior-year quarter, with quarterly revenue projected at $119.1 million, up 45.46% year-over-year [2] - For the full year, analysts expect earnings of $0.70 per share and revenue of $495.8 million, indicating changes of +42.86% and +16.26% respectively from last year [3] Group 3 - Recent modifications to analyst estimates for Adma Biologics reflect short-term business trends, with positive revisions indicating a favorable business outlook [4] - The Zacks Rank system, which incorporates estimate changes, currently ranks Adma Biologics as 2 (Buy), with a 1.46% rise in the Zacks Consensus EPS estimate over the past month [5][6] Group 4 - Adma Biologics has a Forward P/E ratio of 26.52, which is a premium compared to the industry's average Forward P/E of 19.99 [7] - The Medical - Biomedical and Genetics industry holds a Zacks Industry Rank of 73, placing it in the top 30% of over 250 industries [7][8]

Core Viewpoint - ADMA Biologics has demonstrated strong performance in 2024, with continued growth expected in 2025, driven by its lead product Asceniv and new supply contracts [1][8]. Financial Performance - In Q4 2024, ADMA reported adjusted earnings per share of 14 cents, slightly missing the Zacks Consensus Estimate by one cent, while revenues reached $118 million, surpassing the consensus estimate of $112 million [1]. - The company has revised its financial targets, now expecting revenues of over $490 million in 2025 and $605 million in 2026, with net income projected to exceed $175 million in 2025 and $235 million in 2026 [9]. Product and Market Analysis - ADMA Biologics specializes in plasma-derived biologics for treating immune deficiencies and preventing infectious diseases, with three FDA-approved products: Bivigam, Asceniv, and Nabi-HB [3][4]. - Asceniv, the lead product, is a plasma-derived IVIG designed for treating primary immunodeficiency disease (PIDD) and is manufactured using a patented plasma donor screening methodology [5][6]. - Strong demand for Asceniv is anticipated to continue into 2025, with expectations for increased patient starts and market penetration [7]. Supply Chain and Growth Potential - ADMA has entered into long-term high-titer plasma supply contracts, significantly increasing its access to raw material plasma, with a five-fold increase in total collection capacity from approximately 250 collection centers [8]. - Management projects that these supply agreements could position ADMA to achieve $1 billion in total annual revenues before 2030, indicating substantial growth potential in the 2030s [8]. Competitive Landscape - ADMA Biologics competes with Takeda and Grifols in the U.S. market for plasma-derived products, with a targeted market that shows significant growth potential [10].